High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

References

• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018. doi:10.1016/S0140-6736(18)31041-9
   PubMedGoogle Scholar
• Barbui T, Thiele J, Gisslinger H, et al The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi:10.1038/s41408-018-0054-y29426921
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-73319627895058
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C, et al The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–2784. doi:10.1182/blood-2007-08-10909017957027
   PubMed Web of Science ®Google Scholar
• Taskesen E, Bullinger L, Corbacioglu A, et al Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469–2475. doi:10.1182/blood-2010-09-30728021177436
   PubMed Web of Science ®Google Scholar
• Rakheja D, Konoplev S, Medeiros LJ, Chen W. IDH mutations in acute myeloid leukemia. Hum Pathol. 2012;43(10):1541–1551. doi:10.1016/j.humpath.2012.05.00322917530
   PubMed Web of Science ®Google Scholar
• Bowen D, Groves MJ, Burnett AK, et al TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23(1):203–206. doi:10.1038/leu.2008.17318596741
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Bullinger L, Schlenk RF, et al RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29(10):1364–1372. doi:10.1200/JCO.2010.30.792621343560
   PubMed Web of Science ®Google Scholar
• Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica. 2014;99(11):1663–1670. doi:10.3324/haematol.2014.11461125420282
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ, et al Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–2361. doi:10.1001/jama.2009.81319509382
   PubMed Web of Science ®Google Scholar
• Kihara R, Nagata Y, Kiyoi H, et al Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28(8):1586–1595. doi:10.1038/leu.2014.5524487413
   PubMed Web of Science ®Google Scholar
• Yanada M, Mori J, Aoki J, et al Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma. 2018;59(3):601–609. doi:10.1080/10428194.2017.135717328750566
   PubMed Web of Science ®Google Scholar
• Takami A. Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol. 2018;107(5):513–518. doi:10.1007/s12185-018-2412-829374826
   PubMed Web of Science ®Google Scholar
• Rashidi A, Linden MA, DeFor TE, et al History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol. 2017;92(10):1032–1036. doi:10.1002/ajh.2483428646534
   PubMed Web of Science ®Google Scholar
• Araki D, Wood BL, Othus M, et al Allogeneic hematopoietic cell transplantation for Acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34(4):329–336. doi:10.1200/JCO.2015.63.382626668349
   PubMed Web of Science ®Google Scholar
• Chen DJ, Chen W, Jiang H, Yang H, Wang YC, Chen JH. Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial-mesenchymal transition. Drug Des Devel Ther. 2016;10:2845–2853. doi:10.2147/DDDT.S101998
   PubMed Web of Science ®Google Scholar
• Gadea G, Blangy A. Dock-family exchange factors in cell migration and disease. Eur J Cell Biol. 2014;93(10–12):466–477. doi:10.1016/j.ejcb.2014.06.00325022758
   PubMed Web of Science ®Google Scholar
• Laurin M, Huber J, Pelletier A, et al Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis. Proc Natl Acad Sci U S A. 2013;110(18):7434–7439. doi:10.1073/pnas.121305011023592719
   PubMed Web of Science ®Google Scholar
• Lee SH, Chiu YC, Li YH, et al High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia. Oncotarget. 2017;8(42):72250–72259. doi:10.18632/oncotarget.1970629069784
   PubMedGoogle Scholar
• Zhang J, Shi J, Zhang G, et al BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2018;97(8):1391–1397. doi:10.1007/s00277-018-3331-829696374
   PubMed Web of Science ®Google Scholar
• Chou SC, Tang JL, Hou HA, et al Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leuk Res. 2014;38(11):1278–1284. doi:10.1016/j.leukres.2014.08.01225260824
   PubMed Web of Science ®Google Scholar
• Ma Y, Wu Y, Shen Z, Zhang X, Zeng D, Kong P. Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review. Clin Transplant. 2015;29(2):149–160. doi:10.1111/ctr.1249525430616
   PubMed Web of Science ®Google Scholar
• Xu Y, Sun Y, Shen H, et al Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations. Am J Hematol. 2015;90(11):992–997. doi:10.1002/ajh.2413526223865
   PubMed Web of Science ®Google Scholar
• Grimsley CM, Kinchen JM, Tosello-Trampont A-C, et al. Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration. J Biol Chem. 2004;279(7):6087–6097. doi:10.1074/jbc.M30708720014638695
   PubMed Web of Science ®Google Scholar
• Jarzynka MJ, Hu B, Hui KM, et al ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. Cancer Res. 2007;67(15):7203–7211. doi:10.1158/0008-5472.CAN-07-047317671188
   PubMed Web of Science ®Google Scholar
• Jing X, Wu H, Ji X, Wu H, Shi M, Zhao R. Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer. Oncol Rep. 2016;36(4):1946–1952. doi:10.3892/or.2016.505827633051
   PubMed Web of Science ®Google Scholar
• Tajiri H, Uruno T, Shirai T, et al Targeting ras-driven cancer cell survival and invasion through selective inhibition of DOCK1. Cell Rep. 2017;19(5):969–980. doi:10.1016/j.celrep.2017.04.01628467910
   PubMed Web of Science ®Google Scholar